After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper , M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO , Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused

SAN DIEGO , Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga , president and chief executive officer, and Dr.

Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant driver of JEMPERLI royalties Anticipate top-line data from two GSK Phase 3

SAN DIEGO , May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga , interim president and chief executive officer of AnaptysBio , and other members of its

Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1

Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4 Flare control sustained on monthly subcutaneous doses through Week 16 Imsidolimab was generally safe and well tolerated with low overall ADA incidence Top-line GEMINI-1 Phase 3

SAN DIEGO , April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain , M.D., to the company’s Board of Directors, effective immediately.

Results published in The   New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting 72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically

Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023 Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic dermatitis anticipated Q2 2023 Initiating second Phase 2 trial for rosnilimab in an indication to be